Novel STAT 3 inhibitors for treating gastric cancer (Q38870465)

7 September 2017

1 reference

title

Novel STAT 3 inhibitors for treating gastric cancer (English)

1 reference

7 September 2017

1

Catherine Cafferkey

1 reference

7 September 2017

Ian Chau

2

1 reference

PubMed ID

27322026

7 September 2017

language of work or name

English

0 references

publication date

20 June 2016

1 reference

Expert Opinion on Investigational Drugs

7 September 2017

1 reference

7 September 2017

25

1 reference

7 September 2017

9

1 reference

7 September 2017

1023-1031

1 reference

Global cancer statistics, 2012

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

STAT-3 inhibitors: state of the art and new horizons for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1195807

10.1080/13543784.2016.1195807

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27322026